Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 08, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarterSelected...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
August 01, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
July 30, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD)NTLA-3001...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 24, 2024 16:01 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Announces CFO Transition
June 26, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
June 25, 2024 15:30 ET
|
Intellia Therapeutics, Inc.
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28...
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
June 17, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Names Brian Goff to its Board of Directors
June 14, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
June 02, 2024 08:00 ET
|
Intellia Therapeutics, Inc.
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of...
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of...